Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci142 in Bacterial Vaginosis
NCT07663838Phase 1Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Aug 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of human lysozyme in bacterial vaginosis (BV) (2 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoint: Incidence and severity of treatment-emergent adverse events at 30 days. Started Aug 2026; status: recruiting.
02
Drugs
human lysozyme
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on NCT07663838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07663838.